G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
27 Febrero 2024 - 7:30AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced that G1’s Chief Executive Officer Jack
Bailey will participate in a Breast & Lung Cancer Corporate
Panel Discussion during the TD Cowen 44th Annual Health Care
Conference on Wednesday March 6, 2024 at 9:10 AM EST.
The webcast of the event will be accessible on the Events &
Presentations page of http://www.g1therapeutics.com.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage oncology biopharmaceutical company whose mission
is to develop and deliver next-generation therapies that improve
the lives of those affected by cancer, including the Company’s
first commercial product, COSELA® (trilaciclib). The Company is
also evaluating therapies in combination with cytotoxic therapies
and/or immunotherapy in areas of high unmet need including
triple-negative breast cancer and extensive stage small cell lung
cancer. G1’s goal is to provide innovative therapeutic advances for
people living with cancer. G1 is based in Research Triangle Park,
N.C. For additional information, please visit
http://www.g1therapeutics.com and follow us on X (formerly known as
Twitter) @G1Therapeutics and LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and
the COSELA logo are trademarks of G1 Therapeutics, Inc.
Contacts:Will RobertsCommunications OfficerVice
President, Investor Relations and Corporate Communications(919)
907-1944 wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024